TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Study: NCT00483795
Drug: sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05382910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06312176
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT06312176
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05403450
Drug: Decitabine + Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT06179875
Drug: Intervention/Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
Study: NCT05678647
Drug: Iron Sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
Study: NCT04914767
Drug: Nigella
Normalized name: NIGELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Study: NCT04953910
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study: NCT04914767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Study: NCT05663866
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered subcutaneously.
Study: NCT05152147
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally (PO bid)
Study: NCT06337162
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Tablet
Study: NCT04764292
Drug: Iodinated Contrast Media (ICM)
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: supplemental breast cancer screening with contrast-enhanced mammography
Study: NCT06362447
Drug: Gentamicin Injectable Solution
Normalized name: gentamicin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
Study: NCT05514197
Drug: Ascorbic acid 5000mg
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
Study: NCT04600336
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06500676
Drug: GFH375
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT06324357
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda®
Study: NCT06159673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACP-204 matching placebo
Study: NCT04657081
Drug: Decitabine and Cedazuridine (ASTX727)
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: oral in the form of a tablet
Study: NCT05968326
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
Study: NCT05174169
Drug: CAPOX 3 month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
Study: NCT05174169
Drug: CAPOX 6 month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
Study: NCT05060731
Drug: Oral iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
Study: NCT05060731
Drug: Intravenous iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
Study: NCT04739800
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05422222
Drug: VX-121/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination for oral administration.
Study: NCT06658574
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
Study: NCT06662786
Drug: Leucovorin calcium/Levoleucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study: NCT06056804
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825-1000mg/m2,po,bid
Study: NCT06606860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT06600412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please refer to arm/group description for further information.
Study: NCT06360094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05694533
Drug: INDV-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally twice a day
Study: NCT03278730
Drug: Para-Tyrosine supplementation
Normalized name: α-methyl-para-tyrosine
DrugBank: Metyrosine (DB00765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
Study: NCT06397911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Study: NCT06673017
Drug: PTM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTM-101, an absorbable drug product containing paclitaxel
Study: NCT05905783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04542382
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet.
Study: NCT04542382
Drug: Rosuvastatin (Inhibitor arm)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet.
Study: NCT04810091
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06243354
Drug: Test product: HYP-2090PTSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest).
Study: NCT06252649
Drug: FOLFIRI Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
Study: NCT06092970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05838547
Drug: 64Cu-25%-CANF-Comb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 12-18 months, or earlier if they develop symptoms. While 12-18 months is the preferred window for repeat imaging, if imaging during this time frame is not achievable, the patient may return anytime throughout the remainder of the study.
Study: NCT05838547
Drug: 64Cu-25%-CANF-Comb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
Study: NCT05255302
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
Study: NCT05358548
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study: NCT06625411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Study: NCT06625398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Study: NCT06615050
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously (IV)
Study: NCT06615050
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously (IV)
Study: NCT06685757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0.9% saline solution by intravenous infusion.
Study: NCT06682806
Drug: PRT3789
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT3789 is administered as an intravenous infusion once weekly for 3 weeks
Study: NCT06685835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated Oral tablet
Study: NCT06700538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by SC injection
Study: NCT06717152
Drug: SJP-0132
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous eye drop, one drop each time and four times each day, 8 weeks in treatment period in SJP-0132 group.
Study: NCT06717152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.
Study: NCT06704009
Drug: NT-101 0.05 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration of NT-101 (0.05 mM)
Study: NCT06704009
Drug: NT-101 0.2 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration of NT-101 (0.2 mM)
Study: NCT05829460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
Study: NCT06723106
Drug: RAY121
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT06707103
Drug: TR987 0.1% gel + Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
Study: NCT06728553
Drug: MTX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 2 mg sublingual tablet of MTX101
Study: NCT06728553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet of placebo
Study: NCT05981963
Drug: [14C]-BMS-986196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06721871
Drug: Placebo Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Powder for Oral Solution
Study: NCT06717178
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission to the hospital for a new chemotherapy regimen (initial or change)
Study: NCT06732882
Drug: AZD4604
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD4604 via Genuair/Turbuhaler device.
Study: NCT05303792
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05303792
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT05303792
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05303792
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05790213
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).
Study: NCT06736483
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
Study: NCT06741397
Drug: New formulation of CAB LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections administered IM gluteal.
Study: NCT06788912
Drug: Acetaminophen (or equivalent)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
Study: NCT06797635
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Study: NCT06797635
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Study: NCT06797635
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Study: NCT06309966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily
Study: NCT06747845
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.
Study: NCT06761976
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2927088 is self-administered by the patient BID (twice a day) as tablets for oral administration
Study: NCT05286814
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
Study: NCT06588738
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESK-001
Study: NCT06721156
Drug: MK-1167
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1167 oral capsule
Study: NCT06721156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT06428409
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks
Study: NCT06428409
Drug: Leucovorin (LV) or levoleucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV or levoleucovorin is administered by IV infusion every 2 weeks
Study: NCT06428409
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Study: NCT06428409
Drug: Supportive care measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Study: NCT06369285
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter
Study: NCT05206513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
Study: NCT06756451
Drug: RJK-RT2831 Dose Expansion Phase Ib
Approvals — FDA: no, EMA: no, PMDA: no
Description: there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
Study: NCT06172296
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06172296
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06757075
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery
Study: NCT06777979
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT06778863
Drug: CLSP-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLSP-1025 will be administered by IV infusion
Study: NCT06738407
Drug: Doxycycline hyclate delayed released 200 mg
Normalized name: doxycycline hyclate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.
Study: NCT06738407
Drug: Doxycycline hyclate delayed released 200 mg weekly
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of doxycycline taken by mouth weekly regardless of sexual activity